1. Home
  2. Labeler Index
  3. Lundbeck Pharmaceuticals Llc
  4. 67386-130
  5. Product Images: Vyepti

Product Images Vyepti

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Vyepti NDC 67386-130 by Lundbeck Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1. Change from Baseline in Monthly Migraine Days in Study 1 - vyepti 1

Figure 1. Change from Baseline in Monthly Migraine Days in Study 1 - vyepti 1

Figure 2. Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1 to 3 by Treatment Group in Study 1 - vyepti 2

Figure 2. Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1 to 3 by Treatment Group in Study 1 - vyepti 2

This appears to be a table that shows the percentage of patients who experience fewer migraine days per month on placebo vs. two different doses of VYEPTI medication (100 mg quarterly and 300 mg quarterly). The table also displays the number of patients in each group (222 for placebo, and 221 and 222 for the two VYEPTI doses). There are also percentages displayed on the y-axis ranging from 10-30%, and a chart underneath that shows a decrease in migraine days over the course of the study.*

Figure 3. Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 1 - vyepti 3

Figure 3. Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 1 - vyepti 3

This is a chart depicting the percentage of patients with a migraine before and after infusion of different treatments. The treatments mentioned are VYEPTI 300 mg, VYEPTI 100 mg, and Placebo. The chart seems to indicate that VYEPTI 300 mg has a lower percentage of patients with a migraine compared to 100 mg and Placebo. The horizontal axis indicates the number of days post-infusion. Nonetheless, no information is provided regarding the overall efficacy of the treatments or the sample size used to generate these results.*

Figure 4. Change from Baseline in Monthly Migraine Days in Study 2 - vyepti 4

Figure 4. Change from Baseline in Monthly Migraine Days in Study 2 - vyepti 4

Figure 5. Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1-3 by Treatment Group in Study 2 - vyepti 5

Figure 5. Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1-3 by Treatment Group in Study 2 - vyepti 5

This seems to be a chart showing the percentage of patients experiencing a reduction in migraine days per month while taking the medication VYEPTI 100mg or 300mg quarterly, compared to those taking a placebo. The chart also indicates that there were fewer migraine days in those taking VYEPTI, but no change or an increase in migraine days in some patients. The lower section of the chart includes dates and numbers that are difficult to interpret.*

Figure 6. Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 2 - vyepti 6

Figure 6. Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 2 - vyepti 6

This is a graph that shows the percentage of patients with a migraine (measured with standard error) on different days after infusion with either VYEPTI 300 mg, VYEPTI 100 mg or a placebo. The days range from 3 to 4.*

Lundbeck Logo 1 - vyepti 7

Lundbeck Logo 1 - vyepti 7

Lundbeck - vyepti 8

Lundbeck - vyepti 8

NDC 67386-130-51 VYEPTITM (vye ep' tee) (eptinezumab-jjmr) injection, for intravenous use 100 mg/mL injection, for intravenous use 100 mg/mL - vyepti 9

NDC 67386-130-51 VYEPTITM (vye ep' tee) (eptinezumab-jjmr) injection, for intravenous use 100 mg/mL injection, for intravenous use 100 mg/mL - vyepti 9

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.